Novel catheter treatment of valve disease

我们正在继续发展经导管二尖瓣环成形术，这是一种通过利用自然（冠状静脉）和非自然（心内间隔）轨迹在二尖瓣环周围建立环向张力的新技术。我们已经在猪缺血性心肌病模型中建立了主要的证据，证明环扎环成形术可以减少继发性（“功能性”）二尖瓣反流。在我们改进设备的同时，我们正在努力与小型企业签订新的合同，以资助将这种新技术合作转化为患者。

We are continuing development of transcatheter mitral cerclage annuloplasty, a novel technique which establishes circumferential tension around the mitral valve annulus by exploiting both natural (coronary venous) and un-natural (intramyocardial septal) trajectories. We have established proof-of-principal in a porcine model of ischemic cardiomyopathy that cerclage annuloplasty reduces secondary ("functional") mitral valve regurgitation. While we refine devices, we are working to issue new contracts to small businesses to to fund collaborative translation of this novel technique into patients. We have conceived a wholly new approach to treat tricuspid valve regurgitation called transauricular intrapericardial tricuspid annuloplasty (TRAIPTA). We have demonstrated the success of TRAIPTA to reduce functional tricuspid regurgitation in a new animal model. We recently entered into a Collaborative Research and Development Agreement with a large catheter company to develop this technique for testing in patients. We have developed a new technique to introduce large implants into the aorta for transcatheter aortic valve replacement and related procedures, by crossing from the inferior vena cava into the abdominal aorta. This challenges the long-held paradigm that the aortic wall must remain inviolate during non-surgical procedures. The technique has proven lifesaving in over three dozen patients. We are sponsoring a multicenter evaluation of the technique while we develop purpose-built devices to close the access port. This technology has applications in the treatment of numerous congenital heart diseases and in allowing novel non-surgical access to the heart. We are developing an innovative approach to access the heart through the chest wall without surgery. We are working collaboratively with a small business to develop a partial mitral valve replacement without surgery, using a novel outside invention to replace the posterior mitral valve leaflet to treat mitral valve regurgitation whether functional or degenerative.